{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T21:29:10Z","timestamp":1781126950046,"version":"3.54.1"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trop Dis Travel Med Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>For decades, immunoglobulin preparations have been used to prevent or treat infectious diseases. Since only a few years, monoclonal antibody applications (mAbs) are taking flight and are increasingly dominating this field. In 2014, only two mAbs were registered; end of October 2023, more than ten mAbs are registered or have been granted emergency use authorization, and many more are in (pre)clinical phases. Especially the COVID-19 pandemic has generated this surge in licensed monoclonal antibodies, although multiple phase 1 studies were already underway in 2019 for other infectious diseases such as malaria and yellow fever. Monoclonal antibodies could function as prophylaxis (i.e., for the prevention of malaria), or could be used to treat (tropical) infections (i.e., rabies, dengue fever, yellow fever). This review focuses on the discussion of the prospects of, and obstacles for, using mAbs in the prevention and treatment of (tropical) infectious diseases seen in the returning traveler; and provides an update on the mAbs currently being developed for infectious diseases, which could potentially be of interest for travelers.<\/jats:p>","DOI":"10.1186\/s40794-023-00212-x","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:16:17Z","timestamp":1705277777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Monoclonal antibody applications in travel medicine"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6224-7947","authenticated-orcid":false,"given":"Hanna K.","family":"de Jong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-1099","authenticated-orcid":false,"given":"Martin P.","family":"Grobusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"issue":"2","key":"212_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jama.2020.10245","volume":"324","author":"M Marovich","year":"2020","unstructured":"Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA. 2020;324(2):131\u20132.","journal-title":"JAMA"},{"issue":"9","key":"212_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa2034031","volume":"385","author":"MR Gaudinski","year":"2021","unstructured":"Gaudinski MR, Berkowitz NM, Idris AH, Coates EE, Holman LA, Mendoza F, Gordon IJ, Plummer SH, Trofymenko O, Hu Z, et al. A monoclonal antibody for Malaria Prevention. N Engl J Med. 2021;385(9):803\u201314.","journal-title":"N Engl J Med"},{"issue":"5","key":"212_CR3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1056\/NEJMoa2000226","volume":"383","author":"JG Low","year":"2020","unstructured":"Low JG, Ng JHJ, Ong EZ, Kalimuddin S, Wijaya L, Chan YFZ, Ng DHL, Tan HC, Baglody A, Chionh YH, et al. Phase 1 trial of a therapeutic Anti-yellow fever virus human antibody. N Engl J Med. 2020;383(5):452\u20139.","journal-title":"N Engl J Med"},{"issue":"6","key":"212_CR4","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","volume":"21","author":"PC Taylor","year":"2021","unstructured":"Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382\u201393.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"212_CR5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jinf.2016.02.017","volume":"72","author":"RW Wieten","year":"2016","unstructured":"Wieten RW, Goorhuis A, Jonker EFF, de Bree GJ, de Visser AW, van Genderen PJJ, Remmerswaal EBM, Ten Berge IJM, Visser LG, Grobusch MP, et al. 17D Yellow Fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients. J Infect. 2016;72(6):713\u201322.","journal-title":"J Infect"},{"issue":"10","key":"212_CR6","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.vaccine.2016.01.037","volume":"34","author":"RW Wieten","year":"2016","unstructured":"Wieten RW, Jonker EF, Pieren DK, Hodiamont CJ, van Thiel PP, van Gorp EC, de Visser AW, Grobusch MP, Visser LG, Goorhuis A. Comparison of the PRNT and an immune fluorescence assay in Yellow Fever vaccinees receiving immunosuppressive medication. Vaccine. 2016;34(10):1247\u201351.","journal-title":"Vaccine"},{"issue":"9","key":"212_CR7","doi-asserted-by":"publisher","first-page":"e683","DOI":"10.1016\/S2666-5247(22)00123-9","volume":"3","author":"Y Gao","year":"2022","unstructured":"Gao Y, Zhao Y, Guyatt G, Fowler R, Kojan R, Ge L, Tian J, Collaborators, Hao Q. Effects of therapies for Ebola virus Disease: a systematic review and network meta-analysis. Lancet Microbe. 2022;3(9):e683-692.","journal-title":"Lancet Microbe"},{"issue":"11","key":"212_CR8","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012628","volume":"12","author":"GD de Melo","year":"2020","unstructured":"de Melo GD, Sonthonnax F, Lepousez G, Jouvion G, Minola A, Zatta F, Larrous F, Kergoat L, Mazo C, Moigneu C, et al. A combination of two human monoclonal antibodies cures symptomatic rabies. EMBO Mol Med. 2020;12(11): e12628.","journal-title":"EMBO Mol Med"},{"issue":"37","key":"212_CR9","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1016\/j.vaccine.2018.06.061","volume":"36","author":"World Health O","year":"2018","unstructured":"World Health O. Rabies vaccines: WHO position paper, April 2018 - recommendations. Vaccine. 2018;36(37):5500\u20133.","journal-title":"Vaccine"},{"issue":"1","key":"212_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa1511812","volume":"374","author":"J van Griensven","year":"2016","unstructured":"van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba N, Antierens A, et al. Evaluation of convalescent plasma for Ebola Virus Disease in Guinea. N Engl J Med. 2016;374(1):33\u201342.","journal-title":"N Engl J Med"},{"issue":"1","key":"212_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1086\/344905","volume":"36","author":"AC Jackson","year":"2003","unstructured":"Jackson AC, Warrell MJ, Rupprecht CE, Ertl HC, Dietzschold B, O\u2019Reilly M, Leach RP, Fu ZF, Wunner WH, Bleck TP, et al. Management of rabies in humans. Clin Infect Dis. 2003;36(1):60\u20133.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"212_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41573-022-00495-3","volume":"21","author":"G Pantaleo","year":"2022","unstructured":"Pantaleo G, Correia B, Fenwick C, Joo VS, Perez L. Antibodies to combat viral Infections: development strategies and progress. Nat Rev Drug Discov. 2022;21(9):676\u201396.","journal-title":"Nat Rev Drug Discov"},{"issue":"7838","key":"212_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41586-020-2838-z","volume":"588","author":"S Bournazos","year":"2020","unstructured":"Bournazos S, Corti D, Virgin HW, Ravetch JV. Fc-optimized antibodies elicit CD8 immunity to viral Respiratory Infection. Nature. 2020;588(7838):485\u201390.","journal-title":"Nature"},{"issue":"5517","key":"212_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G Kohler","year":"1975","unstructured":"Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495\u20137.","journal-title":"Nature"},{"issue":"4","key":"212_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrd3003","volume":"9","author":"TT Hansel","year":"2010","unstructured":"Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325\u201338.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"212_CR16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/00006454-199802000-00006","volume":"17","author":"KN Subramanian","year":"1998","unstructured":"Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sanchez PJ, Steichen J, Givner LB, Jennings TL, Top FH Jr, Carlin D, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17(2):110\u20135.","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"212_CR17","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","volume":"5","author":"WS Lee","year":"2020","unstructured":"Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020;5(10):1185\u201391.","journal-title":"Nat Microbiol"},{"key":"212_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101427","volume":"50","author":"S Pecetta","year":"2020","unstructured":"Pecetta S, Finco O, Seubert A. Quantum Leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era. Semin Immunol. 2020;50: 101427.","journal-title":"Semin Immunol"},{"issue":"4","key":"212_CR19","doi-asserted-by":"publisher","first-page":"e225750","DOI":"10.1001\/jamanetworkopen.2022.5750","volume":"5","author":"M Park","year":"2022","unstructured":"Park M, Tan KB, Vasoo S, Dickens BL, Lye D, Cook AR. Estimated health outcomes and costs associated with use of monoclonal antibodies for prevention or mitigation of SARS-CoV-2 Infections. JAMA Netw Open. 2022;5(4):e225750.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"212_CR20","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1080\/13543784.2016.1240785","volume":"25","author":"AL Moekotte","year":"2016","unstructured":"Moekotte AL, Huson MA, van der Ende AJ, Agnandji ST, Huizenga E, Goorhuis A, Grobusch MP. Monoclonal antibodies for the treatment of Ebola virus Disease. Expert Opin Investig Drugs. 2016;25(11):1325\u201335.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"212_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/07388551.2015.1114465","volume":"37","author":"E Gonzalez-Gonzalez","year":"2017","unstructured":"Gonzalez-Gonzalez E, Alvarez MM, Marquez-Ipina AR, Trujillo-de Santiago G, Rodriguez-Martinez LM, Annabi N, Khademhosseini A. Anti-ebola therapies based on monoclonal antibodies: current state and challenges ahead. Crit Rev Biotechnol. 2017;37(1):53\u201368.","journal-title":"Crit Rev Biotechnol"},{"key":"212_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2020.100001","volume":"1","author":"MP Grobusch","year":"2021","unstructured":"Grobusch MP, Weld L, Goorhuis A, Hamer DH, Schunk M, Jordan S, Mockenhaupt FP, Chappuis F, Asgeirsson H, Caumes E, et al. Travel-related Infections presenting in Europe: a 20-year analysis of EuroTravNet surveillance data. Lancet Reg Health Eur. 2021;1: 100001.","journal-title":"Lancet Reg Health Eur"},{"issue":"3","key":"212_CR23","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1016\/S1473-3099(16)30545-X","volume":"17","author":"MC Castro","year":"2017","unstructured":"Castro MC, Wilson ME, Bloom DE. Disease and economic burdens of dengue. Lancet Infect Dis. 2017;17(3):e70-78.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"212_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1800820","volume":"379","author":"S Sridhar","year":"2018","unstructured":"Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, Savarino S, Zambrano B, Moureau A, Khromava A, et al. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. N Engl J Med. 2018;379(4):327\u201340.","journal-title":"N Engl J Med"},{"issue":"6","key":"212_CR25","doi-asserted-by":"publisher","first-page":"e2021055522","DOI":"10.1542\/peds.2021-055522","volume":"149","author":"JM Wong","year":"2022","unstructured":"Wong JM, Adams LE, Durbin AP, Munoz-Jordan JL, Poehling KA, Sanchez-Gonzalez LM, Volkman HR, Paz-Bailey G. Dengue: a growing Problem with New interventions. Pediatrics. 2022;149(6):e2021055522.","journal-title":"Pediatrics"},{"issue":"10234","key":"212_CR26","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","volume":"395","author":"S Biswal","year":"2020","unstructured":"Biswal S, Borja-Tabora C, Martinez Vargas L, Velasquez H, Theresa Alera M, Sierra V, Johana Rodriguez-Arenales E, Yu D, Wickramasinghe VP, Duarte Moreira EJ, et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial. Lancet. 2020;395(10234):1423\u201333.","journal-title":"Lancet"},{"issue":"6525","key":"212_CR27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1126\/science.abb9425","volume":"371","author":"N Modhiran","year":"2021","unstructured":"Modhiran N, Song H, Liu L, Bletchly C, Brillault L, Amarilla AA, Xu X, Qi J, Chai Y, Cheung STM, et al. A broadly protective antibody that targets the flavivirus NS1 protein. Science. 2021;371(6525):190\u20134.","journal-title":"Science"},{"issue":"6583","key":"212_CR28","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.abn9651","volume":"375","author":"SB Biering","year":"2022","unstructured":"Biering SB. One antibody to treat them all. Science. 2022;375(6583):803.","journal-title":"Science"},{"key":"212_CR29","doi-asserted-by":"publisher","first-page":"27(4)","DOI":"10.1093\/jtm\/taaa061","volume":"27","author":"KM Angelo","year":"2020","unstructured":"Angelo KM, Stoney RJ, Brun-Cottan G, Leder K, Grobusch MP, Hochberg N, Kuhn S, Bottieau E, Schlagenhauf P, Chen L, et al. Zika among international travellers presenting to GeoSentinel sites, 2012\u20132019: implications for clinical practice. J Travel Med. 2020;27:27(4).","journal-title":"J Travel Med"},{"issue":"2","key":"212_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.7326\/M16-1842","volume":"166","author":"DH Hamer","year":"2017","unstructured":"Hamer DH, Barbre KA, Chen LH, Grobusch MP, Schlagenhauf P, Goorhuis A, van Genderen PJ, Molina I, Asgeirsson H, Kozarsky PE, et al. Travel-Associated Zika Virus Disease Acquired in the Americas through February 2016: a GeoSentinel Analysis. Ann Intern Med. 2017;166(2):99\u2013108.","journal-title":"Ann Intern Med"},{"issue":"10107","key":"212_CR31","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/S0140-6736(17)31450-2","volume":"390","author":"D Baud","year":"2017","unstructured":"Baud D, Gubler DJ, Schaub B, Lanteri MC, Musso D. An update on Zika virus Infection. Lancet. 2017;390(10107):2099\u2013109.","journal-title":"Lancet"},{"issue":"10022","key":"212_CR32","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(16)00502-X","volume":"387","author":"O Karimi","year":"2016","unstructured":"Karimi O, Goorhuis A, Schinkel J, Codrington J, Vreden SGS, Vermaat JS, Stijnis C, Grobusch MP. Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus Infection. Lancet. 2016;387(10022):939\u201340.","journal-title":"Lancet"},{"issue":"5","key":"212_CR33","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ymthe.2019.03.005","volume":"27","author":"RN Esquivel","year":"2019","unstructured":"Esquivel RN, Patel A, Kudchodkar SB, Park DH, Stettler K, Beltramello M, Allen JW, Mendoza J, Ramos S, Choi H, et al. In vivo delivery of a DNA-Encoded monoclonal antibody protects non-human Primates against Zika Virus. Mol Ther. 2019;27(5):974\u201385.","journal-title":"Mol Ther"},{"key":"212_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tmaid.2017.01.004","volume":"15","author":"M van Aalst","year":"2017","unstructured":"van Aalst M, Nelen CM, Goorhuis A, Stijnis C, Grobusch MP. Long-term sequelae of Chikungunya virus Disease: a systematic review. Travel Med Infect Dis. 2017;15:8\u201322.","journal-title":"Travel Med Infect Dis"},{"issue":"6","key":"212_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005637","volume":"11","author":"R Broeckel","year":"2017","unstructured":"Broeckel R, Fox JM, Haese N, Kreklywich CN, Sukulpovi-Petty S, Legasse A, Smith PP, Denton M, Corvey C, Krishnan S, et al. Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of Chikungunya virus Disease in rhesus macaques. PLoS Negl Trop Dis. 2017;11(6): e0005637.","journal-title":"PLoS Negl Trop Dis"},{"issue":"375","key":"212_CR36","doi-asserted-by":"publisher","first-page":"eaah3438","DOI":"10.1126\/scitranslmed.aah3438","volume":"9","author":"JJ Miner","year":"2017","unstructured":"Miner JJ, Cook LE, Hong JP, Smith AM, Richner JM, Shimak RM, Young AR, Monte K, Poddar S, Crowe JE Jr, et al. Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls Chikungunya virus arthritis. Sci Transl Med. 2017;9(375):eaah3438.","journal-title":"Sci Transl Med"},{"issue":"12","key":"212_CR37","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","volume":"27","author":"A August","year":"2021","unstructured":"August A, Attarwala HZ, Himansu S, Kalidindi S, Lu S, Pajon R, Han S, Lecerf JM, Tomassini JE, Hard M, et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat Med. 2021;27(12):2224\u201333.","journal-title":"Nat Med"},{"key":"212_CR38","first-page":"204993612211026","volume":"9","author":"M Caldwell","year":"2022","unstructured":"Caldwell M, Boruah AP, Thakur KT. Acute neurologic emerging flaviviruses. Ther Adv Infect Dis. 2022;9:20499361221102664.","journal-title":"Ther Adv Infect Dis"},{"issue":"26","key":"212_CR39","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1016\/j.vaccine.2022.04.079","volume":"40","author":"N Islam","year":"2022","unstructured":"Islam N, Xu C, Lau CL, Mills DJ, Clark J, Devine GJ, Hugo LE, Gyawali N, Thalib L, Furuya-Kanamori L. Persistence of antibodies, boostability, and interchangeability of Japanese encephalitis vaccines: a systematic review and dose-response meta-analysis. Vaccine. 2022;40(26):3546\u201355.","journal-title":"Vaccine"},{"issue":"4","key":"212_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122608","volume":"10","author":"A Rayamajhi","year":"2015","unstructured":"Rayamajhi A, Nightingale S, Bhatta NK, Singh R, Kneen R, Ledger E, Bista KP, Lewthwaite P, Mahaseth C, Turtle L, et al. A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PLoS ONE. 2015;10(4): e0122608.","journal-title":"PLoS ONE"},{"issue":"8","key":"212_CR41","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S1473-3099(15)00134-6","volume":"15","author":"H Patel","year":"2015","unstructured":"Patel H, Sander B, Nelder MP. Long-term sequelae of West Nile virus-related Illness: a systematic review. Lancet Infect Dis. 2015;15(8):951\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"212_CR42","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1128\/AAC.01178-09","volume":"54","author":"JH Beigel","year":"2010","unstructured":"Beigel JH, Nordstrom JL, Pillemer SR, Roncal C, Goldwater DR, Li H, Holland PC, Johnson S, Stein K, Koenig S. Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus. Antimicrob Agents Chemother. 2010;54(6):2431\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"212_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001638","volume":"11","author":"T Garske","year":"2014","unstructured":"Garske T, Van Kerkhove MD, Yactayo S, Ronveaux O, Lewis RF, Staples JE, Perea W, Ferguson NM. Yellow Fever Expert C: Yellow Fever in Africa: estimating the burden of Disease and impact of mass vaccination from outbreak and serological data. PLoS Med. 2014;11(5): e1001638.","journal-title":"PLoS Med"},{"issue":"9190","key":"212_CR44","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/S0140-6736(99)09233-8","volume":"354","author":"D Teichmann","year":"1999","unstructured":"Teichmann D, Grobusch MP, Wesselmann H, Temmesfeld-Wollbruck B, Breuer T, Dietel M, Emmerich P, Schmitz H, Suttorp N. A haemorrhagic Fever from the Cote d\u2019Ivoire. Lancet. 1999;354(9190):1608.","journal-title":"Lancet"},{"key":"212_CR45","doi-asserted-by":"crossref","unstructured":"Jacob ST, Crozier I, Fischer WA 2, Hewlett A, Kraft CS, Vega MA, Soka MJ, Wahl V, Griffiths A, Bollinger L, et al. Ebola virus Disease. Nat Rev Dis Primers. 2020;6(1):13.","DOI":"10.1038\/s41572-020-0147-3"},{"key":"212_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tmaid.2018.06.009","volume":"24","author":"MP Grobusch","year":"2018","unstructured":"Grobusch MP, Schaumburg F, Weitzel T, Rothe C, Hanscheid T, Goorhuis A. Ebola 2018 - implications for travel health advice and relevance for travel medicine. Travel Med Infect Dis. 2018;24:1\u20133.","journal-title":"Travel Med Infect Dis"},{"issue":"26","key":"212_CR47","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1056\/NEJMoa2200072","volume":"387","author":"PS Team","year":"2022","unstructured":"Team PS, Kieh M, Richert L, Beavogui AH, Grund B, Leigh B, D\u2019Ortenzio E, Doumbia S, Lhomme E, Sow S, et al. Randomized Trial of vaccines for Zaire Ebola Virus Disease. N Engl J Med. 2022;387(26):2411\u201324.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"212_CR48","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1086\/514298","volume":"179","author":"K Mupapa","year":"1999","unstructured":"Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, Colebunders R, Muyembe-Tamfum JJ. Treatment of Ebola hemorrhagic Fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis. 1999;179(Suppl 1):18\u201323.","journal-title":"J Infect Dis"},{"issue":"13","key":"212_CR49","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1073\/pnas.1200409109","volume":"109","author":"JM Dye","year":"2012","unstructured":"Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, Ortiz RA, Prugar LI, Pratt WD. Postexposure antibody prophylaxis protects nonhuman primates from filovirus Disease. Proc Natl Acad Sci U S A. 2012;109(13):5034\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"212_CR50","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3201\/eid2103.141838","volume":"21","author":"TR Kreil","year":"2015","unstructured":"Kreil TR. Treatment of Ebola virus Infection with antibodies from reconvalescent donors. Emerg Infect Dis. 2015;21(3):521\u20133.","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"212_CR51","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.tmrv.2020.04.001","volume":"34","author":"HC Sullivan","year":"2020","unstructured":"Sullivan HC, Roback JD. Convalescent plasma: therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic. Transfus Med Rev. 2020;34(3):145\u201350.","journal-title":"Transfus Med Rev"},{"issue":"48","key":"212_CR52","doi-asserted-by":"publisher","first-page":"17182","DOI":"10.1073\/pnas.1414164111","volume":"111","author":"CD Murin","year":"2014","unstructured":"Murin CD, Fusco ML, Bornholdt ZA, Qiu X, Olinger GG, Zeitlin L, Kobinger GP, Ward AB, Saphire EO. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci U S A. 2014;111(48):17182\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"212_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2022.101210","volume":"54","author":"H Fausther-Bovendo","year":"2022","unstructured":"Fausther-Bovendo H, Kobinger G. The road to effective and accessible antibody therapies against Ebola virus. Curr Opin Virol. 2022;54: 101210.","journal-title":"Curr Opin Virol"},{"issue":"15","key":"212_CR54","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","volume":"375","author":"PIW Group","year":"2016","unstructured":"Group PIW, Multi-National PIIST, Davey RT Jr, Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS, Beigel J, Tierney J, et al. A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. N Engl J Med. 2016;375(15):1448\u201356.","journal-title":"N Engl J Med"},{"issue":"24","key":"212_CR55","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","volume":"381","author":"S Mulangu","year":"2019","unstructured":"Mulangu S, Dodd LE, Davey RT Jr, Mbaya T, Proschan O, Mukadi M, Lusakibanza Manzo D, Nzolo M, Tshomba Oloma D, Ibanda A. A Randomized, Controlled Trial of Ebola Virus Disease therapeutics. N Engl J Med. 2019;381(24):2293\u2013303.","journal-title":"N Engl J Med"},{"issue":"12","key":"212_CR56","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1056\/NEJMc2113505","volume":"386","author":"S Mulangu","year":"2022","unstructured":"Mulangu S, Mbala-Kingebeni P, Mbaya OT. Antibody use during an outbreak of Ebola Virus Disease in the Democratic Republic of Congo, 2020. N Engl J Med. 2022;386(12):1188\u201391.","journal-title":"N Engl J Med"},{"key":"212_CR57","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ijid.2021.09.053","volume":"113","author":"M Jaspard","year":"2021","unstructured":"Jaspard M, Juchet S, Serra B, Mayoum B, Kanta IM, Camara MS, Mbala P, Kojan R, Malvy D. Post-exposure prophylaxis following high-risk contact with Ebola virus, using immunotherapies with monoclonal antibodies, in the eastern Democratic Republic of the Congo: an emergency use program. Int J Infect Dis. 2021;113:166\u20137.","journal-title":"Int J Infect Dis"},{"issue":"10381","key":"212_CR58","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","volume":"401","author":"WJ Jeng","year":"2023","unstructured":"Jeng WJ, Papatheodoridis GV, Lok ASF. Hepatitis B. Lancet. 2023;401(10381):1039\u201352.","journal-title":"Lancet"},{"issue":"11","key":"212_CR59","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00535-016-1189-x","volume":"51","author":"M Tsuge","year":"2016","unstructured":"Tsuge M, Hiraga N, Uchida T, Kan H, Miyaki E, Masaki K, Ono A, Nakahara T, Abe-Chayama H, Zhang Y, et al. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic Hepatitis B Infection. J Gastroenterol. 2016;51(11):1073\u201380.","journal-title":"J Gastroenterol"},{"issue":"4","key":"212_CR60","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1136\/gutjnl-2015-310978","volume":"65","author":"C Sureau","year":"2016","unstructured":"Sureau C. A unique monoclonal antibody for therapeutic use against chronic Hepatitis B: not all antibodies are created equal. Gut. 2016;65(4):546\u20137.","journal-title":"Gut"},{"issue":"13","key":"212_CR61","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1016\/j.cgh.2019.09.038","volume":"18","author":"HW Lee","year":"2020","unstructured":"Lee HW, Park JY, Hong T, Park MS, Ahn SH. Efficacy of Lenvervimab, a recombinant human immunoglobulin, in treatment of Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2020;18(13):3043-3045e3041.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"17","key":"212_CR62","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","volume":"374","author":"ST Agnandji","year":"2016","unstructured":"Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, et al. Phase 1 trials of rVSV Ebola Vaccine in Africa and Europe. N Engl J Med. 2016;374(17):1647\u201360.","journal-title":"N Engl J Med"},{"issue":"8","key":"212_CR63","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","volume":"19","author":"MP Manns","year":"2022","unstructured":"Manns MP, Maasoumy B. Breakthroughs in Hepatitis C research: from discovery to cure. Nat Rev Gastroenterol Hepatol. 2022;19(8):533\u201350.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"212_CR64","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/ajt.12083","volume":"13","author":"RT Chung","year":"2013","unstructured":"Chung RT, Gordon FD, Curry MP, Schiano TD, Emre S, Corey K, Markmann JF, Hertl M, Pomposelli JJ, Pomfret EA, et al. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant. 2013;13(4):1047\u201354.","journal-title":"Am J Transplant"},{"issue":"5","key":"212_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063818","volume":"8","author":"D Gardiner","year":"2013","unstructured":"Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R, Reddy KR, Chang KM, Sulkowski M, Marro SO, Anderson J, et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic Hepatitis C virus Infection. PLoS ONE. 2013;8(5): e63818.","journal-title":"PLoS ONE"},{"issue":"8","key":"212_CR66","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/jvh.12369","volume":"22","author":"W Halota","year":"2015","unstructured":"Halota W, Ferenci P, Kozielewicz D, Dybowska D, Lisovoder N, Samira S, Shalit I, Ellis R, Ilan Y. Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial. J Viral Hepat. 2015;22(8):651\u20137.","journal-title":"J Viral Hepat"},{"issue":"1","key":"212_CR67","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","volume":"59","author":"B Sangro","year":"2013","unstructured":"Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic Hepatitis C. J Hepatol. 2013;59(1):81\u20138.","journal-title":"J Hepatol"},{"key":"212_CR68","doi-asserted-by":"publisher","first-page":"102520","DOI":"10.1016\/j.tmaid.2022.102520","volume":"52","author":"JL Schnyder","year":"2022","unstructured":"Schnyder JL, de Jong HK, Bache EB, van Hest RM, Schlagenhauf P, Borrmann S, Hanscheid T, Grobusch MP. On the potential for discontinuing atovaquone-proguanil (AP) ad-hoc post-exposure and other abbreviated AP-regimens: Pharmacology, pharmacokinetics and perspectives. Travel Med Infect Dis. 2022;52:102520.","journal-title":"Travel Med Infect Dis"},{"issue":"24","key":"212_CR69","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","volume":"367","author":"SCTP Rts","year":"2012","unstructured":"Rts SCTP, Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmuller B, Issifou S, et al. A phase 3 trial of RTS,S\/AS01 Malaria vaccine in African infants. N Engl J Med. 2012;367(24):2284\u201395.","journal-title":"N Engl J Med"},{"issue":"11","key":"212_CR70","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMp2116591","volume":"386","author":"PL Alonso","year":"2022","unstructured":"Alonso PL, O\u2019Brien KL. A Malaria Vaccine for Africa - An important step in a Century-Long Quest. N Engl J Med. 2022;386(11):1005\u20137.","journal-title":"N Engl J Med"},{"issue":"4","key":"212_CR71","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.4512","volume":"24","author":"NK Kisalu","year":"2018","unstructured":"Kisalu NK, Idris AH, Weidle C, Flores-Garcia Y, Flynn BJ, Sack BK, Murphy S, Schon A, Freire E, Francica JR, et al. A human monoclonal antibody prevents Malaria Infection by targeting a new site of vulnerability on the parasite. Nat Med. 2018;24(4):408\u201316.","journal-title":"Nat Med"},{"issue":"5","key":"212_CR72","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1473-3099(22)00793-9","volume":"23","author":"KE Lyke","year":"2023","unstructured":"Lyke KE, Berry AA, Mason K, Idris AH, O\u2019Callahan M, Happe M, Strom L, Berkowitz NM, Guech M, Hu Z, et al. Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against Malaria (VRC 612 part C): a phase 1, adaptive trial. Lancet Infect Dis. 2023;23(5):578\u201388.","journal-title":"Lancet Infect Dis"},{"issue":"20","key":"212_CR73","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1056\/NEJMoa2206966","volume":"387","author":"K Kayentao","year":"2022","unstructured":"Kayentao K, Ongoiba A, Preston AC, Healy SA, Doumbo S, Doumtabe D, Traore A, Traore H, Djiguiba A, Li S, et al. Safety and Efficacy of a monoclonal antibody against Malaria in Mali. N Engl J Med. 2022;387(20):1833\u201342.","journal-title":"N Engl J Med"},{"issue":"5","key":"212_CR74","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJMoa2203067","volume":"387","author":"RL Wu","year":"2022","unstructured":"Wu RL, Idris AH, Berkowitz NM, Happe M, Gaudinski MR, Buettner C, Strom L, Awan SF, Holman LA, Mendoza F, et al. Low-dose subcutaneous or intravenous monoclonal antibody to prevent Malaria. N Engl J Med. 2022;387(5):397\u2013407.","journal-title":"N Engl J Med"},{"issue":"11","key":"212_CR75","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/S1473-3099(22)00428-5","volume":"22","author":"SC van der Boor","year":"2022","unstructured":"van der Boor SC, Smit MJ, van Beek SW, Ramjith J, Teelen K, van de Vegte-Bolmer M, van Gemert GJ, Pickkers P, Wu Y, Locke E, et al. Safety, tolerability, and Plasmodium Falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults. Lancet Infect Dis. 2022;22(11):1596\u2013605.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"212_CR76","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1093\/infdis\/jiab034","volume":"226","author":"CA De Pijper","year":"2022","unstructured":"De Pijper CA, Langedijk AC, Terryn S, Van Gucht S, Grobusch MP, Goorhuis A, Stijnis C. Long-term memory response after a single intramuscular rabies booster vaccination 10\u201324 years after primary immunization. J Infect Dis. 2022;226(6):1052\u20136.","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"212_CR77","doi-asserted-by":"publisher","first-page":"A132","DOI":"10.1016\/j.vaccine.2018.11.004","volume":"37","author":"E Sparrow","year":"2019","unstructured":"Sparrow E, Torvaldsen S, Newall AT, Wood JG, Sheikh M, Kieny MP, Abela-Ridder B. Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: a review of the current status of the clinical development pipeline. Vaccine. 2019;37(Suppl 1):A132-139.","journal-title":"Vaccine"},{"key":"212_CR78","doi-asserted-by":"crossref","unstructured":"Whitehouse ER, Mandra A, Bonwitt J, Beasley EA, Taliano J, Rao AK. Human rabies despite post-exposure prophylaxis: a systematic review of fatal breakthrough Infections after zoonotic exposures. Lancet Infect Dis 2022.","DOI":"10.1016\/S1473-3099(22)00641-7"},{"issue":"50","key":"212_CR79","doi-asserted-by":"publisher","first-page":"7315","DOI":"10.1016\/j.vaccine.2012.09.027","volume":"30","author":"N Gogtay","year":"2012","unstructured":"Gogtay N, Thatte U, Kshirsagar N, Leav B, Molrine D, Cheslock P, Kapre SV, Kulkarni PS. Group SIIRa: Safety and pharmacokinetics of a human monoclonal antibody to Rabies virus: a randomized, dose-escalation phase 1 study in adults. Vaccine. 2012;30(50):7315\u201320.","journal-title":"Vaccine"},{"issue":"3","key":"212_CR80","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/cid\/cix791","volume":"66","author":"NJ Gogtay","year":"2018","unstructured":"Gogtay NJ, Munshi R, Ashwath Narayana DH, Mahendra BJ, Kshirsagar V, Gunale B, Moore S, Cheslock P, Thaker S, Deshpande S, et al. Comparison of a Novel human rabies monoclonal antibody to human rabies immunoglobulin for Postexposure Prophylaxis: a phase 2\/3, Randomized, Single-Blind, Noninferiority, controlled study. Clin Infect Dis. 2018;66(3):387\u201395.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"212_CR81","doi-asserted-by":"publisher","first-page":"e2722","DOI":"10.1093\/cid\/ciaa779","volume":"73","author":"K Kansagra","year":"2021","unstructured":"Kansagra K, Parmar D, Mendiratta SK, Patel J, Joshi S, Sharma N, Parihar A, Bhoge S, Patel H, Kalita P, et al. A phase 3, Randomized, Open-label, Noninferiority Trial Evaluating Anti-rabies Monoclonal Antibody Cocktail (TwinrabTM) against Human Rabies Immunoglobulin (HRIG). Clin Infect Dis. 2021;73(9):e2722-2728.","journal-title":"Clin Infect Dis"},{"issue":"40","key":"212_CR82","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.1016\/j.vaccine.2021.08.066","volume":"39","author":"JB McClain","year":"2021","unstructured":"McClain JB, Chuang A, Reid C, Moore SM, Tsao E. Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: results of a phase 2, randomized, blinded, controlled trial. Vaccine. 2021;39(40):5822\u201330.","journal-title":"Vaccine"},{"issue":"42","key":"212_CR83","doi-asserted-by":"publisher","first-page":"6153","DOI":"10.1016\/j.vaccine.2022.09.022","volume":"40","author":"L Li","year":"2022","unstructured":"Li L, Li Y, Bai Y, Li G, Zhang J, Yang L, Zhao W, Zhao W, Luo F, Zhao Q, et al. Neutralizing antibody activity, safety and immunogenicity of human anti-rabies virus monoclonal antibody (Ormutivimab) in Chinese healthy adults: a phase \u00e2\u00a1b randomized, double-blind, parallel-controlled study. Vaccine. 2022;40(42):6153\u201362.","journal-title":"Vaccine"},{"key":"212_CR84","doi-asserted-by":"publisher","first-page":"798078","DOI":"10.1155\/2014\/798078","volume":"2014","author":"IR Pereira","year":"2014","unstructured":"Pereira IR, Vilar-Pereira G, Silva AA, Moreira OC, Britto C, Sarmento ED, Lannes-Vieira J. Tumor necrosis factor is a therapeutic target for immunological unbalance and cardiac abnormalities in chronic experimental Chagas\u2019 Heart Disease. Mediators Inflamm. 2014;2014:798078.","journal-title":"Mediators Inflamm"},{"issue":"10","key":"212_CR85","doi-asserted-by":"publisher","DOI":"10.1111\/pim.12724","volume":"42","author":"MA Hasby Saad","year":"2020","unstructured":"Hasby Saad MA, El-Anwar N. Bevacizumab as a potential anti-angiogenic therapy in schistosomiasis: a double-edged, but adjustable weapon. Parasite Immunol. 2020;42(10): e12724.","journal-title":"Parasite Immunol"},{"issue":"1","key":"212_CR86","doi-asserted-by":"publisher","first-page":"e0004022","DOI":"10.1128\/cmr.00040-22","volume":"36","author":"R Kumari","year":"2023","unstructured":"Kumari R, Sharma SD, Kumar A, Ende Z, Mishina M, Wang Y, Falls Z, Samudrala R, Pohl J, Knight PR, et al. Antiviral approaches against Influenza Virus. Clin Microbiol Rev. 2023;36(1):e0004022.","journal-title":"Clin Microbiol Rev"},{"issue":"11","key":"212_CR87","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1016\/S1473-3099(22)00311-5","volume":"22","author":"D Focosi","year":"2022","unstructured":"Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect Dis. 2022;22(11):e311-326.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"212_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1443-1","volume":"18","author":"AJ Browne","year":"2020","unstructured":"Browne AJ, Kashef Hamadani BH, Kumaran EAP, Rao P, Longbottom J, Harriss E, Moore CE, Dunachie S, Basnyat B, Baker S, et al. Drug-resistant enteric Fever worldwide, 1990 to 2018: a systematic review and meta-analysis. BMC Med. 2020;18(1): 1.","journal-title":"BMC Med"},{"issue":"3","key":"212_CR89","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.3139","volume":"37","author":"B Kelley","year":"2021","unstructured":"Kelley B, Renshaw T, Kamarck M. Process and operations strategies to enable global access to antibody therapies. Biotechnol Prog. 2021;37(3): e3139.","journal-title":"Biotechnol Prog"},{"issue":"5","key":"212_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0001432","volume":"3","author":"RS Laufer","year":"2023","unstructured":"Laufer RS, Baral R, Buchwald AG, Campbell JD, Coulibaly F, Diallo F, Doumbia M, Driscoll AJ, Galvani AP, Keita AM, et al. Optimizing next-generation RSV prevention in Mali: a cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis. PLOS Glob Public Health. 2023;3(5):e0001432.","journal-title":"PLOS Glob Public Health"},{"issue":"1","key":"212_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007860","volume":"14","author":"R van Hooft","year":"2020","unstructured":"van Hooft R, Kojima S, Carter D, Okabe H, Sato A, Akahata W, Wells TNC, Katsuno K. Reassessing therapeutic antibodies for neglected and Tropical Diseases. PLoS Negl Trop Dis. 2020;14(1): e0007860.","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"212_CR92","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/btpr.2492","volume":"33","author":"J Pollock","year":"2017","unstructured":"Pollock J, Coffman J, Ho SV, Farid SS. Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture. Biotechnol Prog. 2017;33(4):854\u201366.","journal-title":"Biotechnol Prog"}],"container-title":["Tropical Diseases, Travel Medicine and Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40794-023-00212-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40794-023-00212-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40794-023-00212-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:17:53Z","timestamp":1705277873000},"score":1,"resource":{"primary":{"URL":"https:\/\/tdtmvjournal.biomedcentral.com\/articles\/10.1186\/s40794-023-00212-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["212"],"URL":"https:\/\/doi.org\/10.1186\/s40794-023-00212-x","relation":{},"ISSN":["2055-0936"],"issn-type":[{"value":"2055-0936","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]},"assertion":[{"value":"6 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}